• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MediciNova, Inc. - Common Stock (NQ:MNOV)

    1.580 +0.140 (+9.72%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 347,754
    Open 1.480
    Bid (Size) 1.460 (600)
    Ask (Size) 1.630 (400)
    Prev. Close 1.440
    Today's Range 1.480 - 1.630
    52wk Range 1.130 - 2.060
    Shares Outstanding 49,046,246
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    2026 New Year’s Greetings from the CEO
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
    From MediciNova, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +18.8%
    +18.8%
    1 Month
    +6.8%
    +6.8%
    3 Month
    +26.4%
    +26.4%
    6 Month
    +28.5%
    +28.5%
    1 Year
    -15.5%
    -15.5%

    More News

    Read More
    News headline image
    MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Stock Rockets 85% After-Hours On Promising Heart Study — Traders Hope For ‘Big Green Candle’ ↗
    Via Stocktwits
    News headline image
    Message from the CEO to MediciNova Shareholders
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    Unusual volume stocks in Monday's session ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga
    News headline image
    Which stocks are experiencing notable movement on Friday? ↗
    Via Chartmill
    News headline image
    These stocks have an unusual volume in today's session ↗
    Via Chartmill
    News headline image
    Why Amazon Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    News headline image
    Why Did MediciNova Stock (MNOV) Jump Over 87% In After-Hours Trading? ↗
    Via Benzinga
    News headline image
    MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova to Present at the LD Micro Main Event XIX Investor Conference
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Provides Shareholder Update on Key Developments
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025
    From MediciNova, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is MediciNova, Inc. - Common Stock publicly traded?
    Yes, MediciNova, Inc. - Common Stock is publicly traded.
    What exchange does MediciNova, Inc. - Common Stock trade on?
    MediciNova, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for MediciNova, Inc. - Common Stock?
    The ticker symbol for MediciNova, Inc. - Common Stock is MNOV on the Nasdaq Stock Market
    What is the current price of MediciNova, Inc. - Common Stock?
    The current price of MediciNova, Inc. - Common Stock is 1.580
    When was MediciNova, Inc. - Common Stock last traded?
    The last trade of MediciNova, Inc. - Common Stock was at 01/15/26 04:00 PM ET
    What is the market capitalization of MediciNova, Inc. - Common Stock?
    The market capitalization of MediciNova, Inc. - Common Stock is 77.49M
    How many shares of MediciNova, Inc. - Common Stock are outstanding?
    MediciNova, Inc. - Common Stock has 77M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.